



August 05, 2024

To

BSE Limited

Phiroze Jeejeebhoy Towers,

Dalal Street, Mumbai – 400 001

Tel: 022 - 2272 1233 /4

Fax: 022 – 22721919

Ref: Aragen Life Sciences Limited

Scrip Code: 973783

ISIN: INE483I07010

Sub: Publication of Extract of Financial Results in an English national daily newspaper

In compliance with Regulation 52 (8) of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, the Company has, on Monday, 05th August 2024, published in the 'Business Standard', an English national daily newspaper, the extract of the Financial Results of the Company for the quarter ended 30th June 2024. A copy of the newspaper publication is enclosed herewith.

Please take on your records.

For Aragen Life Sciences Limited

Kasturi
Ramakrishna
a

Digitally signed by
Kasturi Ramakrishna
Date: 2024.08.05
18:20:57 +05'30'

Ramakrishna Kasturi

Company Secretary & Compliance Officer

ARAGEN LIFE SCIENCES LIMITED

(formerly known as Aragen Life Sciences Private Limited)

CIN: U74999TG2000PLC035826

Registered and Corporate Office: Plot 28A, IDA Nacharam,
Hyderabad, Telangana-500076, India

Tel: +91 40 6692 9999 F: +91 40 6692 9900

Email id: compliances@aragen.com, website: www.aragen.com



Extract of standalone financial results for the quarter ended 30 June 2024

(amount in ₹ million)

S. No.	Particulars	Quarter ended		Year ended	
		30 June 2024 Unaudited	31 March 2024 Audited (Refer Note 6)	30 June 2023 Unaudited	31 March 2024 Audited
1	Total Income from operations	3,897.36	3,736.29	3,419.28	14,602.08
2	Net Profit / (Loss) for the period (before tax, Exceptional and/or extraordinary items)	644.63	626.65	497.19	2,517.19
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or extraordinary items)	644.63	626.65	497.19	2,517.19
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or extraordinary items)	485.43	471.11	373.14	1,887.66
5	Total Comprehensive Income for the period/Year [Comprising Profit for the period (after tax) and Other Comprehensive Income (after tax)]	510.69	474.89	563.61	2,022.22
6	Paid up Equity Share Capital (Face value of ₹ 10/- each)	2,044.14	2,044.14	2,044.14	2,044.14
7	Reserves (excluding Revaluation Reserve)				11,727.60
8	Securities Premium Account	0	0	0	0
9	Net worth	14,301.41	13,771.74	12,768.09	13,771.74
10	Paid up Debt Capital	5,881.01	6,004.48	5,193.68	6,004.48
11	Outstanding Redeemable Preference Shares	N.A.	N.A.	N.A.	N.A.
12	Debt Equity Ratio	0.42	0.44	0.41	0.44
13	Earnings Per Share (EPS) (Face value of ₹ 10 each fully paid) *				
	Basic EPS (Rs)	2.40	2.33	1.85	9.34
	Diluted EPS (Rs)	2.37	2.30	1.82	9.21
14	Capital Redemption Reserve	--	--	--	--
15	Debenture Redemption Reserve	200.00	200.00	200.00	200.00
16	Debt Service Coverage Ratio	1.22	1.30	3.63	1.21
17	Interest Service Coverage Ratio	6.12	6.40	6.46	6.99

*EPS not annualised for the quarter ended.

Notes:

1. The above is an extract of the detailed format of quarterly/annual financial results filed with the Stock Exchange(s) under regulation 52 of the Listing Regulations. The above financial results have been reviewed and recommended by the Audit Committee at its meeting held on 29 July 2024 and approved by the Board of Directors at its meeting held on 02 August 2024. These Financial Results have been prepared in accordance with the recognition and measurement principles of Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act 2013 read with the relevant rules there under and the other accounting principles generally accepted in India.
2. For the other line items referred in Regulation 52(4) of the LODR Regulations, pertinent disclosures have been made to the stock exchange, BSE Limited, and can be accessed at www.bseindia.com. The full format of the quarterly/annual financial results including detailed notes thereon are available on the websites of the stock exchange- BSE Limited at www.bseindia.com and the Company at www.aragen.com.
3. During the year ended 31 March 2022, the Company had issued 2,000 rated, listed, redeemable, Non-convertible Debentures (NCDs) of face value ₹1,000,000 each for a total amount of ₹ 2,000 million on a private placement basis. These NCDs have been listed on the Stock Exchange (BSE Limited) with effect from 14 February 2022. The NCDs are repayable at the end of 36 months from the date of allotment and carry an annual interest rate of 7.75% per annum due on 11 February of every year.
4. In terms of regulation 54(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the NCDs are secured by first charge on Property, plant & equipment, movable CWIP including immovable property at Mallapur unit with minimum asset cover of 1.25x.
5. During the quarter ended 30 June 2024, the Company had not received any complaints from the NCD holders and there has been no complaint pending for redressal at the beginning or at the end of the quarter. The equity shares of the Company are not listed on any Stock Exchange.
6. Figures for the quarter ended 31 March 2024 represents the balancing figure between the audited figures in respect of the full financial year and the unaudited year to date figures up to the third quarter of the respective financial years.
7. The statutory auditors of the Company ("B S R and Co") have carried out a limited review of the above unaudited standalone financial results for the quarter ended 30 June 2024 and have issued an unmodified review report. The review report of the Statutory auditors was filed with the BSE Limited and also is available on the Company's website.
8. Subsequent to Quarter ended 30 June 2024, the Company has transferred its 100% stake in Aragen Bioscience, Inc., to its wholly owned subsidiary, i.e., Aragen Biologics Private Limited on 02 July 2024.

For Aragen Life Sciences Limited

Sd/-
Manmohesh Kantipudi
Whole-time Director & CEO
DIN:05241166

Date : 02 August 2024
Place : Hyderabad